ACE Pharmaceuticals Manufacturing and Packaging of Clinical Trial Medication

ACE Pharmaceuticals offers a full range of custom-designed development services with professional standards. Further to that ACE offers manufacturing and packaging of clinical trial medication. We specialize in solid, semi-solid and liquid pharmaceutical products. In a strategic alliance with other companies we can offer you parenteral formulations: ampoules, vials, lyophilised and terminally sterilized processes for single and multi-dose products, small molecules and peptides / proteins and sterility assurance / process validation.

The solutions we offer are tailored to our customers’ exact needs, modular services with the overriding objective of accelerating commercial success. Our expertise covers API characterization, pre-formulation, formulation development, validation and analytical method development. Our GMP-license states that ACE is authorised to manufacture and supply (worldwide) investigational medicinal products for clinical trial purposes.

Our track record includes over 20 products, which have either performed development work, and/or manufactured clinical trial medication, which are now registered products.


Our laboratory is a certified, independently operating analytical laboratory, providing advanced and sophisticated analytical services with experienced professionals and state-of-the-art instrumentation (Certificate 103441 EL, issued by the Ministry of Health). The ACE laboratory has a strong commitment towards quality assurance and provides quality and excellence in analytical support. ACE operates cGMP guidelines and ICH-guidelines.


Our development methods include:

  • Analysis of active ingredients as such, in blends and finished products such as soft and hard gel caps, tablets and capsules
  • Quantitative and qualitative characterization of impurities, residual solvents etc
  • Assays and dissolution tests of finished products according to EP, BP, USP and JP-guidelines
  • Analytical method validation and method development services
  • Clinical trial analytical support
  • Pharmaceutical equivalence studies
  • Finished product stability studies


Our service covers the clinical supply process from clinical manufacture to drug destruction in quantities ranging from Phase I and compassionate use requests to large-scale Phase III/IV studies involving multinational centres. It includes packaging, labelling and distribution services for patient administration at investigational sites worldwide. When it comes to driving project completion, ACE Pharmaceuticals provides unsurpassed attention to detail. We deliver always on time, at the right place, in the right quality and the requested quantity for a fair price.


Creation of clinical trial pack design or pack design according to requirement of customer are processed under a number of sections. Our primary packaging includes blinding by over-encapsulation, manufacturing of placebo capsules, blister packaging (PVC, PVDC, PVC/PE/PVDC, Aclar, Aluminium, etc), mixed fill blisters and bottling of tablets and capsules.

Our secondary packaging includes various and complex pack assemblies (open, single blind, double blind, double dummy), cold seal walleting / carding of blisters and coding by inkjet printer (invisible ink).

Finally our labelling services cover the design and generation of labels, multilingual labels, labels printed by thermal transfer, coloured labels or coloured printing, over labelling and design and generation of code break envelopes.


Storage, distribution and returns:

  • GMP storage facilities: at room temperature or between 2°C and 8°C
  • Monitoring of temperature and humidity
  • Worldwide distribution (to clinical centres, investigators and/or sponsors)
  • Receipt, evaluation and reconciliation of returns
  • Destruction of returns


Full project management includes randomisation of treatments, protocol development, advice and consultation worldwide; dynamic and GMP/GCP experimented staff.


Permanent training of operators and the maintenance of our quality system have allowed us to reach an excellent level of quality and to obtain the manufacturer authorisation (license 3103A/d) issued by the Dutch Ministry of Health. This certificate is based on the application of Good Manufacturing Practices and ICH-guidelines dedicated to clinical supplies.

Make an enquiry

ACE Pharmaceuticals BV

PO Box 1262

NL-3890 BB Zeewolde



+31 36 5227201 +31 36 5229096

ACE Pharmaceuticals Images

Products and Services


White Papers

Related Projects

Vraylar (cariprazine) for the Treatment of Bipolar Disorder and Schizophrenia

Vraylar (cariprazine) is a once-daily, oral, atypical antipsychotic drug indicated for the treatment of adults with bipolar I disorder and schizophrenia.

15th May 2020

Lokelma (sodium zirconium cyclosilicate) for the Treatment of Adults with Hyperkalaemia

Lokelma is an oral suspension of sodium zirconium cyclosilicate that is indicated for the treatment of patients with hyperkalaemia.

6th July 2018

Endari for the Treatment of Sickle Cell Disease

Endari™ is an orally administered powdered form of amino acid L-glutamine indicated for the treatment of sickle-cell disease.

25th January 2018

Nuplazid (pimavanserin) for the treatment of Parkinson’s Disease Psychosis (PDP)

Nuplazid (pimavanserin) is an investigational drug for the treatment of Parkinson’s Disease Psychosis (PDP).

9th January 2018

Lartruvo (olaratumab) for the Treatment of Soft Tissue Sarcoma

Developed by Eli Lilly and Company, Lartruvo (olaratumab) in combination with doxorubicin is indicated for the treatment of soft tissue sarcoma (STS) in adult patients. The drug is available as a 10mg/ml injection.

13th September 2017

MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C

MAVYRET™ (glecaprevir/pibrentasvir) was developed by US-based biopharmaceutical company AbbVie as a pan-genotypic treatment for adults suffering from chronic hepatitis C virus (HCV) infection across six major genotypes (GT1 to GT6).

8th August 2017

Tecentriq (atezolizumab) for the Treatment of Metastatic Urothelial Carcinoma (mUC)

Tecentriq® (atezolizumab) is a monoclonal antibody designed to bind with a protein called PD-L1.

31st May 2017

Kanuma (sebelipase alfa) for the Treatment of Lysosomal Acid Lipase Deficiency (LAL-D)

Kanuma™ (sebelipase alfa) is an enzyme replacement therapy (ERT) for the treatment of patients of all ages with lysosomal acid lipase deficiency (LAL-D).

21st January 2016

Ninlaro (ixazomib) for the Treatment of Multiple Myeloma

Ninlaro (ixazomib) is a proteasome inhibitor indicated for the treatment of multiple myeloma.

24th November 2015

Abilify (aripiprazole) Digital Medicine for Treatment of Schizophrenia

Abilify (aripiprazole), an orally administered dopamine partial agonist and a seratonin antagonist, was approved by US Food and Drug Administration (FDA) in November 2002 for the treatment of schizophrenia.

23rd November 2015

Iluvien for the Treatment of Diabetic Macular Oedema

Iluvien is indicated for the treatment of diabetic macular oedema, an eye disease that affects the retina.

29th April 2010

Press Release

Regional Offices

ACE Pharmaceuticals BV

PO Box 1262

NL-3890 BB Zeewolde



+31 36 5227201 +31 36 5229096

Go Top